Real‐world epidemiology and treatment patterns of patients with locally advanced or metastatic urothelial carcinoma: Retrospective analysis of Diagnosis Procedure Combination claims data in Japan
International Journal of Urology · 2024
DOI: 10.1111/iju.15450 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Urology, 2024. Verfasst von Keiko Asakawa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Global Medical Affairs Japan, Astellas Pharma, Inc., Tokyo, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Carcinoma, Transitional Cell. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Seagen, Astellas Pharma.
Abstract (Originalsprache)
Objectives
Evaluate real‐world epidemiologic trends and treatment patterns in newly diagnosed patients with locally advanced or metastatic urothelial carcinoma (la/mUC) in Japan.
Methods
This retrospective analysis included adults with newly diagnosed la/mUC in Japan (January 2015–December 2019) from a nationwide‐linked electronic medical record Diagnostic Procedure Combination claims dataset. Outcomes included epidemiologic trends (incidence and prevalence), baseline demographics, clinical characteristics, and treatment patterns in newly diagnosed patients with la/mUC before (2015–2017) and after (2018–2019) approval of pembrolizumab in Japan.
Results
Of 975 patients included, 76.4% were men; 71.6% were aged 70 years or older. Most cases (70.5%) were of the bladder. Between 2015 and 2019, the annual age‐adjusted incidence increased from 6.8 to 12.4 per 100 000; the annual age‐adjusted period prevalence increased from 13.0 to 25.2 per 100 000; and 307 (31.5%) and 668 (68.5%) patients were diagnosed from 2015 to 2017 and 2018 to 2019, respectively. Overall, 731 (75%) patients received systemic anticancer therapy; all received 1 line and 50.2% received 2 lines of therapy; 78.3% of patients received gemcitabine plus platinum‐based therapy and 2.2% received pembrolizumab as first‐line treatment. First‐line treatment rates increased from 69.4% to 77.5% after pembrolizumab approval. Of 367 patients who received second‐line treatment, 22.3% received gemcitabine plus platinum‐based therapy; 14.7% received pembrolizumab.
Conclusions
In the Japanese regions considered, incidence and prevalence of newly diagnosed la/mUC increased over time and first‐line treatment with pembrolizumab increased after approval.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Global Medical Affairs Japan, Astellas Pharma, Inc., Tokyo, Japan.
- Secondary Data Evidence Generation, Adelphi Real World, Bollington, UK.
- Department of Urology, Tsukuba University, Tsukuba, Japan.
Förderung
- Seagen
- Astellas Pharma
Zitieren
APA
Asakawa, K., Waratani, M., Massey, O., Holbrook, T., Kondo, M., Saito, A., & Nishiyama, H. (2024). Real‐world epidemiology and treatment patterns of patients with locally advanced or metastatic urothelial carcinoma: Retrospective analysis of Diagnosis Procedure Combination claims data in Japan. International Journal of Urology. https://doi.org/10.1111/iju.15450
Vancouver
Asakawa K, Waratani M, Massey O, Holbrook T, Kondo M, Saito A, et al. Real‐world epidemiology and treatment patterns of patients with locally advanced or metastatic urothelial carcinoma: Retrospective analysis of Diagnosis Procedure Combination claims data in Japan. International Journal of Urology. 2024. doi:10.1111/iju.15450
BibTeX
@article{Asakawa2024,
author = {Asakawa, Keiko and Waratani, Miina and Massey, Olivia and Holbrook, Tim and Kondo, Makoto and Saito, Atsushi and Nishiyama, Hiroyuki},
title = {Real‐world epidemiology and treatment patterns of patients with locally advanced or metastatic urothelial carcinoma: Retrospective analysis of Diagnosis Procedure Combination claims data in Japan},
journal = {International Journal of Urology},
year = {2024},
doi = {10.1111/iju.15450}
}
EUVIMED